NCT01938573View on ClinicalTrials.gov

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 18, 2016

Study Completion Date

August 18, 2016

Conditions
Recurrent Bladder CarcinomaStage II Bladder CancerStage III Bladder CancerStage IV Bladder Cancer
Interventions
DRUG

Cisplatin

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Sirolimus

Given PO

PROCEDURE

Cystectomy

Undergo cystectomy when appropriate

Trial Locations (2)

98101

VA Puget Sound Health Care System, Seattle

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT01938573 - Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer | Biotech Hunter | Biotech Hunter